Saccharomyces cerevisiae-derived mannan does not alter immune responses to Aspergillus allergens

D. Betty Lew, Kim S. LeMessurier, Maneesha Palipane, Yanyan Lin, Amali Samarasinghe

Research output: Contribution to journalArticle

Abstract

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Severe asthma with fungal sensitization predominates in the population suffering from allergic asthma, to which there is no cure. While corticosteroids are the mainstay in current treatment, other means of controlling inflammation may be beneficial.Herein, we hypothesized thatmannan fromSaccharomyces cerevisiaewould dampen the characteristics of fungal allergic asthma by altering the pulmonary immune responses. Using wild-type and transgenic mice expressing the human mannose receptor on smooth muscle cells, we explored the outcome of mannan administration during allergen exposure on the pathogenesis of fungal asthma through measurement of cardinal features of disease such as inflammation, goblet cell number, and airway hyperresponsiveness. Mannan treatment did not alter most hallmarks of allergic airways disease in wild-type mice. Transgenic mice treated with mannan during allergen exposure had an equivalent response to non-mannan-treated allergic mice except for a prominent granulocytic influx into airways and cytokine availability. Our studies suggest no role for mannan as an inflammatory regulator during fungal allergy.

Original languageEnglish (US)
Article number3298378
JournalBioMed Research International
Volume2018
DOIs
StatePublished - Jan 1 2018

Fingerprint

Mannans
Aspergillus
Yeast
Allergens
Saccharomyces cerevisiae
Asthma
Transgenic Mice
Inflammation
Allergies
Goblet Cells
Smooth Muscle Myocytes
Reproduction
Muscle
Adrenal Cortex Hormones
Hypersensitivity
Cell Count
Cells
Availability
Cytokines
Lung

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)

Cite this

Saccharomyces cerevisiae-derived mannan does not alter immune responses to Aspergillus allergens. / Lew, D. Betty; LeMessurier, Kim S.; Palipane, Maneesha; Lin, Yanyan; Samarasinghe, Amali.

In: BioMed Research International, Vol. 2018, 3298378, 01.01.2018.

Research output: Contribution to journalArticle

Lew, D. Betty ; LeMessurier, Kim S. ; Palipane, Maneesha ; Lin, Yanyan ; Samarasinghe, Amali. / Saccharomyces cerevisiae-derived mannan does not alter immune responses to Aspergillus allergens. In: BioMed Research International. 2018 ; Vol. 2018.
@article{bb768273d9c74a56919c9b6d80c5880b,
title = "Saccharomyces cerevisiae-derived mannan does not alter immune responses to Aspergillus allergens",
abstract = "which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Severe asthma with fungal sensitization predominates in the population suffering from allergic asthma, to which there is no cure. While corticosteroids are the mainstay in current treatment, other means of controlling inflammation may be beneficial.Herein, we hypothesized thatmannan fromSaccharomyces cerevisiaewould dampen the characteristics of fungal allergic asthma by altering the pulmonary immune responses. Using wild-type and transgenic mice expressing the human mannose receptor on smooth muscle cells, we explored the outcome of mannan administration during allergen exposure on the pathogenesis of fungal asthma through measurement of cardinal features of disease such as inflammation, goblet cell number, and airway hyperresponsiveness. Mannan treatment did not alter most hallmarks of allergic airways disease in wild-type mice. Transgenic mice treated with mannan during allergen exposure had an equivalent response to non-mannan-treated allergic mice except for a prominent granulocytic influx into airways and cytokine availability. Our studies suggest no role for mannan as an inflammatory regulator during fungal allergy.",
author = "Lew, {D. Betty} and LeMessurier, {Kim S.} and Maneesha Palipane and Yanyan Lin and Amali Samarasinghe",
year = "2018",
month = "1",
day = "1",
doi = "10.1155/2018/3298378",
language = "English (US)",
volume = "2018",
journal = "BioMed Research International",
issn = "2314-6133",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Saccharomyces cerevisiae-derived mannan does not alter immune responses to Aspergillus allergens

AU - Lew, D. Betty

AU - LeMessurier, Kim S.

AU - Palipane, Maneesha

AU - Lin, Yanyan

AU - Samarasinghe, Amali

PY - 2018/1/1

Y1 - 2018/1/1

N2 - which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Severe asthma with fungal sensitization predominates in the population suffering from allergic asthma, to which there is no cure. While corticosteroids are the mainstay in current treatment, other means of controlling inflammation may be beneficial.Herein, we hypothesized thatmannan fromSaccharomyces cerevisiaewould dampen the characteristics of fungal allergic asthma by altering the pulmonary immune responses. Using wild-type and transgenic mice expressing the human mannose receptor on smooth muscle cells, we explored the outcome of mannan administration during allergen exposure on the pathogenesis of fungal asthma through measurement of cardinal features of disease such as inflammation, goblet cell number, and airway hyperresponsiveness. Mannan treatment did not alter most hallmarks of allergic airways disease in wild-type mice. Transgenic mice treated with mannan during allergen exposure had an equivalent response to non-mannan-treated allergic mice except for a prominent granulocytic influx into airways and cytokine availability. Our studies suggest no role for mannan as an inflammatory regulator during fungal allergy.

AB - which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Severe asthma with fungal sensitization predominates in the population suffering from allergic asthma, to which there is no cure. While corticosteroids are the mainstay in current treatment, other means of controlling inflammation may be beneficial.Herein, we hypothesized thatmannan fromSaccharomyces cerevisiaewould dampen the characteristics of fungal allergic asthma by altering the pulmonary immune responses. Using wild-type and transgenic mice expressing the human mannose receptor on smooth muscle cells, we explored the outcome of mannan administration during allergen exposure on the pathogenesis of fungal asthma through measurement of cardinal features of disease such as inflammation, goblet cell number, and airway hyperresponsiveness. Mannan treatment did not alter most hallmarks of allergic airways disease in wild-type mice. Transgenic mice treated with mannan during allergen exposure had an equivalent response to non-mannan-treated allergic mice except for a prominent granulocytic influx into airways and cytokine availability. Our studies suggest no role for mannan as an inflammatory regulator during fungal allergy.

UR - http://www.scopus.com/inward/record.url?scp=85041183087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041183087&partnerID=8YFLogxK

U2 - 10.1155/2018/3298378

DO - 10.1155/2018/3298378

M3 - Article

VL - 2018

JO - BioMed Research International

JF - BioMed Research International

SN - 2314-6133

M1 - 3298378

ER -